Remission endpoints in ulcerative colitis: A systematic review
Remission endpoints in ulcerative colitis: A systematic review作者机构：Colorectal Department Singleton Hospital Abertawe Bro Morgannwg University Health Board
出 版 物：《World Journal of Meta-Analysis》 (世界荟萃分析杂志)
年 卷 期：2017年第5卷第4期
页 面：85-102页
学科分类：0710[理学-生物学] 12[管理学] 1204[管理学-公共管理] 120402[管理学-社会医学与卫生事业管理(可授管理学、医学学位)] 1004[医学-公共卫生与预防医学(可授医学、理学学位)] 10[医学]
主 题：Ulcerative colitis Remission Ulcerative colitis endoscopic index of severity Ulcerative disease activity index
摘 要：AIM To summarize the current consensus on the defnition of remission and the endpoints employed in clinical *** bibliogragraphic search was performed from 1946 to 2016 sing online databases （National Library of Medicine’s PubMed Central Medline, OVID SP MEDLINE, OVID EMBASE, the Cochrane Library and Conference Abstracts） with key words： （“ulcerative colitis） AND （“ulcerative colitis endoscopic index of severity OR “UCEIS） AND （“remission） as well as （“ulcerative colitis） AND （“ulcerative colitis disease activity index） OR “UCDAI OR “UC disease activity index OR “Sutherland index） AND （“remission）.RESULTSThe search returned 37 and 116 articles for the UCEIS and UCDAI respectively. For the UCEIS, 12 articles were cited in the final analysis of which 9 validation studies have been identified. Despite the UCEIS has been more extensively validated in all three aspects （validity, responsiveness and reliability）, it has been little employed to monitor disease in randomised clinical trials. For the UCDAI, 37 articles were consider-ed for the final analysis. Although the UCDAI is only partially validated, 29 randomised clinical trials were acknowledged to use the UCDAI to determine endpoints and disease remission, though no clear protocol was *** the UCEIS has been more widely validated than the UCDAI, it has not been refected in the moni-toring of disease activity in clinical trials. Conversely, the UCDAI has been used in numerous large clinical trials to defne their endpoints and disease remission, however, it is challenging to determine the best possible outcomes due to a lack of homogeneity of the clinical trial protocols. Before determining a gold standard index, international agreement on remission is urgently needed to advance patient care.
维普期刊数据库